首页> BMC cancer> Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.

Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.

导出 OA

翻译打印收藏纠错

第一作者： Merin,Babu

第一单位： Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India.

作者： Merin,Babu ^[1] ; Ashok Sebastian,Komaranchath ^[2] ; Arun,Valsan ^[3] ; Arun R,Warrier ^[2] ; Rakesh,Mp ^[1] ; Wesley M,Jose ^[1] ; Nikhil K,Haridas ^[1] ; Sumi,Soman ^[1] ; Manjima P,Nair ^[3] ; Shine,Sadasivan ^[4] ; Abhinav,Menon ^[2] ; Mohammed,Thabrez ^[2] ; Keechilat,Pavithran ^[5]

作者单位： Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India. ^[1] Department of Medical Oncology, Aster Medcity, Kochi, Kerala, India. ^[2] Department of Hepatology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India. ^[3] Department of Gastroenterology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India. ^[4] Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India. pavithrank@aims.amrita.edu. ^[5]

关键词 atezolizumab bevacizumab hepatocellular carcinoma immune checkpoint inhibitors real world